BENGALURU : Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in COVID-19 patients at less than ₹5,000 ($66), the company said.Cipla and privately held Indian drugmaker Hetero Labs on Sunday gained approval to sell generic versions of remdesivir in the country.
Hetero expects to price a similar 100 milligram dose of the treatment at ₹5,000 to 6,000.Beximco Pharmaceuticals Ltd, one of Bangladesh's largest drugmakers, in May became the first company in the world to introduce a generic variant of remdesivir.Reuters exclusively reported that the company was planning to price its version at between 5,000 to 6,000 takas ($59 to $71) per vial.Remdesivir, intravenously administered.